ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,275.38
0.54%
Dow Jones
38,686.32
1.51%
Gold vs US Dollar
2,327.375
0.00%
Brent Oil
81.295
0.00%
Bitcoin
67,646.47
-0.12%
Pepperstone
Advertisement
Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Intellia Therapeutics Inc (NTLA)

  7. Intellia Therapeutics Inc (NTLA) News

Intellia Therapeutics (NTLA)

Intellia Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:NTLA
DateTimeSourceHeadlineSymbolCompany
02/06/202413:00GlobeNewswire Inc.Intellia Therapeutics Announces Positive Long-Term Data from Ongoing Phase 1 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE)NASDAQ:NTLAIntellia Therapeutics Inc
09/05/202421:25Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:NTLAIntellia Therapeutics Inc
09/05/202412:40Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NTLAIntellia Therapeutics Inc
09/05/202412:30GlobeNewswire Inc.Intellia Therapeutics Announces First Quarter 2024 Financial Results and Highlights Recent Company ProgressNASDAQ:NTLAIntellia Therapeutics Inc
02/05/202412:30GlobeNewswire Inc.Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2024 Earnings and Company UpdatesNASDAQ:NTLAIntellia Therapeutics Inc
29/04/202412:30GlobeNewswire Inc.Intellia Therapeutics to Present Updated Data from Phase 1/2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the EAACI Congress 2024NASDAQ:NTLAIntellia Therapeutics Inc
18/03/202411:30GlobeNewswire Inc.Intellia Therapeutics Announces First Patient Dosed in the Phase 3 MAGNITUDE Study of NTLA-2001 as a Single-Dose CRISPR-Based Treatment for Transthyretin Amyloidosis with CardiomyopathyNASDAQ:NTLAIntellia Therapeutics Inc
05/03/202421:10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NTLAIntellia Therapeutics Inc
05/03/202421:10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NTLAIntellia Therapeutics Inc
05/03/202421:10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NTLAIntellia Therapeutics Inc
05/03/202421:10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NTLAIntellia Therapeutics Inc
05/03/202421:10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NTLAIntellia Therapeutics Inc
26/02/202412:04Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:NTLAIntellia Therapeutics Inc
23/02/202422:17Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NTLAIntellia Therapeutics Inc
22/02/202421:11Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:NTLAIntellia Therapeutics Inc
22/02/202421:02Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:NTLAIntellia Therapeutics Inc
22/02/202412:45Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NTLAIntellia Therapeutics Inc
22/02/202412:30GlobeNewswire Inc.Intellia Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Company ProgressNASDAQ:NTLAIntellia Therapeutics Inc
15/02/202412:30Business WireIntellia Therapeutics and ReCode Therapeutics Announce Strategic Collaboration to Develop Novel Gene Editing Therapies for Cystic FibrosisNASDAQ:NTLAIntellia Therapeutics Inc
15/02/202412:30GlobeNewswire Inc.Intellia Therapeutics and ReCode Therapeutics Announce Strategic Collaboration to Develop Novel Gene Editing Therapies for Cystic FibrosisNASDAQ:NTLAIntellia Therapeutics Inc
14/02/202412:30GlobeNewswire Inc.Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2023 Earnings and Company UpdatesNASDAQ:NTLAIntellia Therapeutics Inc
01/02/202421:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NTLAIntellia Therapeutics Inc
31/01/202422:00GlobeNewswire Inc.Intellia Therapeutics Announces Publication of Positive Interim Phase 1 Data for NTLA-2002 in Patients with Hereditary Angioedema in the New England Journal of MedicineNASDAQ:NTLAIntellia Therapeutics Inc
29/01/202421:00Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:NTLAIntellia Therapeutics Inc
10/01/202421:15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NTLAIntellia Therapeutics Inc
08/01/202421:05Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:NTLAIntellia Therapeutics Inc
05/01/202421:50Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NTLAIntellia Therapeutics Inc
05/01/202421:50Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NTLAIntellia Therapeutics Inc
05/01/202421:46Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NTLAIntellia Therapeutics Inc
05/01/202421:45Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NTLAIntellia Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:NTLA

Your Recent History

LSE
ZED
Zenova
LSE
CHLL
Chill Brands
LSE
VAST
Vast Resources
LSE
SAR
Sareum
LSE
KEFI
Kefi Gold And Copper
LSE
BIRD
Blackbird
LSE
GOLD
LSE
GKP
Gulf Keystone Petroleum
LSE
POS
Plexus
LSE
LLOY
Lloyds Banking
LSE
AAZ
Anglo Asian Mining
LSE
AVCT
Avacta
LSE
AGL
Angle
LSE
KRS
Keras Resources
LSE
RKH
Rockhopper Exploration
LSE
BARC
Barclays
Delayed Upgrade Clock
    ADVFN Logo
    InvestorsHub

    United Kingdom
    Company
    Business
    Popular
    Get The App
    App Store
    Google Play

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved